Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Helen Torley, President and CEO of Halozyme Therapeutics (NASDAQ: HALO), sold 10,000 shares on April 6, 2026 under a pre-set 10b5-1 plan for $634,981 and simultaneously exercised options to acquire 10,000 shares at $12.07. The company reported robust revenue gains but a non-GAAP diluted loss per share driven by acquisition-related write-offs; analy…
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe completed an exercise of options and an associated sale of Class A shares on April 6, 2026. The transactions — executed under a pre-arranged Rule 10b5-1 trading plan — coincided with company news of a partnership with Novo Nordisk to offer FDA-approved GLP-1 medications and with a notab…
Ulta Beauty director George R. Mrkonic Jr. sold 452 shares of the company's common stock on April 7, 2026, for a weighted average price of $539.29, totaling $243,759. The sale, carried out by the company's chief legal officer under a power of attorney, leaves Mrkonic with 2,383 shares. Analysts continue to rate the stock favorably overall but offer…
Luke Stevens Putman, senior vice president and general counsel of Black Stone Minerals, L.P., sold 29,386 common units on April 6, 2026, generating proceeds of $424,677. The transaction occurred as the partnership's shares traded close to a 52-week high, after a fourth-quarter earnings and revenue beat and amid an InvestingPro assessment that the s…
On April 7, 2026, Mastin Celeste Beeks, president and CEO of Fuller H B Co (NYSE: FUL), bought 5,170 shares for $57.08 each, a $295,103 transaction that raised his indirectly held stake. The purchase occurred while the stock traded near $57.78, close to its 52-week low, and follows a quarterly earnings report that missed analysts' expectations.
Intellicheck CEO Bryan Lewis sold 10,000 shares on April 6, 2026, at $7.5254 under a Rule 10b5-1 plan and transferred 80,000 shares to The Lewis Family Revocable Living Trust. The stock is trading near its 52-week high after a 221% year-over-year gain, and the company reported Q4 2025 results that exceeded expectations on both earnings and revenue.
Amanda J. Thompson, Gap Inc.'s Chief People Officer, sold 25,000 shares of common stock on April 6, 2026, for a weighted average price of $25.1354, generating roughly $628,385. Following the transactions she retains direct ownership of 86,228 shares. The stock is trading at $24.73 versus an InvestingPro Fair Value of $30.08. Separately, Gap reporte…
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend sold 55,000 shares on April 6, 2026, in a transaction totaling $313,137, according to an SEC Form 4. The sale, carried out under a Rule 10b5-1 plan adopted November 13, 2025, occurred as the company presented clinical data for AAV-based therapies LX2006 and LX2020 and announced senio…
Vir Biotechnology CEO Marianne De Backer sold 72,559 shares on April 6, 2026, through an automatic Rule 10b5-1 plan to satisfy tax obligations tied to restricted stock unit vesting. The trade, totaling about $664,350 at $9.156 per share, leaves her with substantial direct and indirect holdings. Separately, Vir completed a public offering that broug…
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics (NASDAQ: UTHR), sold 7,351 shares on April 6, 2026, for roughly $5.58 million and exercised options to buy 10,000 shares at $135.42. The trades come as the stock nears a 52-week high following positive Phase 3 TETON-1 results for Tyvaso and subsequent analyst target upgrad…
Melissa McLaughlin, Chief Human Resources Officer at Alnylam Pharmaceuticals (ALNY), sold 3,902 shares in early April 2026 for total proceeds of $1.27 million. The disposition included transactions executed to satisfy minimum statutory tax withholding and additional sales under a pre-arranged Rule 10b5-1(c) trading plan adopted in December 2025. Af…
Oscar Health Inc. (NASDAQ: OSCR) CEO Mark T. Bertolini bought 1,000,000 Class A shares at $11.92 each, a transaction valued at $11.92 million, while an equal number plus one was withheld to cover taxes tied to performance stock unit settlements. The company's stock rose to $12.97, reflecting an 11% gain over the past week, even as fourth-quarter 20…
Director Frederick Blair Wimbush purchased a total of $5,747 worth of AH Realty Trust (AHRT) common stock across two transactions on April 1-2, 2026. After the buys, Wimbush holds 42,030.627 shares directly plus 12,919 Time-Based LTIP Units. AHRT is trading near its 52-week low and yields 10%; separate company Armada Hoffler reported mixed fourth-q…
Olivier Bron, CEO of Bloomingdale's, sold 7,228 shares of Macy's common stock on April 6, 2026, for about $129,555 to cover tax withholding tied to vesting restricted shares. The sale was non-discretionary. Bron had also exercised options to convert Restricted Stock Units into 13,146 shares on April 3. Macy's reported stronger-than-expected fourth-…
Patrick E. Bowe, a director at Andersons, Inc., sold 15,000 shares on April 6, 2026, for $74.33 each, generating proceeds of $1,114,950. The transaction occurred with the stock trading near its 52-week high after a 104% one-year return. The company reported a fourth-quarter adjusted EPS beat but missed revenue expectations, and announced a reductio…
Didier Papadopoulos, President of Aircraft OEM at Joby Aviation (NYSE: JOBY), sold 3,394 shares on April 6, 2026 under a 10b5-1 plan for $29,731. The trade coincides with continued flight-testing milestones for Joby, including FAA-conforming aircraft trials and regional demonstration flights, while the stock shows mixed recent performance and diffe…
Gregory Bowles, Joby Aviation's Chief Policy Officer, sold 4,720 shares on April 6, 2026, in a transaction valued at $41,347. The sale was executed under a pre-arranged 10b5-1 trading plan adopted in May 2025. The transaction occurred as Joby continues flight testing for FAA Type Inspection Authorization, conducts demonstration flights in the San F…
Macy's SVP and Controller Paul Griscom sold 745 shares on April 6, 2026, receiving $13,353 at a weighted average price of $17.924. Earlier in the month he converted 2,629 restricted stock units into common shares. The stock is trading near an InvestingPro-assessed fair value while analysts offer a range of ratings and price targets following a stro…
Transcontinental Realty Investors INC, a roughly ten percent owner of INCOME OPPORTUNITY REALTY INVESTORS INC (NASDAQ: IOR), purchased 93 shares of IOR common stock across transactions between February 18 and March 30, 2026, investing a total of $1,640 at prices between $17.55 and $17.75. The filings show Transcontinental now directly holds 3,438,6…
Lightwave Logic Director Siraj Nour El-Ahmadi sold 54,536 shares on April 7, 2026, for about $423,199 to cover taxes tied to vested equity awards. The transaction followed a March 31, 2026 option exercise and leaves El-Ahmadi with 97,168 shares. The company recently reported strong revenue growth and a development agreement with Tower Semiconductor…
Gershon M. Distenfeld, a vice president at AllianceBernstein Global High Income Fund Inc., sold 5,462 shares of AWF on February 5, 2026, for $57,733 at $10.57 per share. Earlier, on January 22, 2026, he bought 1,593 shares across two transactions at prices between $10.595 and $10.599 totaling $16,880. After these trades he directly owns 14,801.2209…
Roger E. Susi, the chief executive, president, and chairman of Iradimed Corporation (NASDAQ: IRMD), sold 7,490 shares of common stock on April 6 and 7, 2026, in transactions totaling $717,207. The trades were carried out under a 10b5-1 plan established on November 5, 2025, and executed indirectly through the Phillip Susi 2008 Dynasty Trust. The com…
Robert E. Dixon, CEO and President of MacKenzie Realty Capital, Inc. (NASDAQ:MKZR), acquired 10,000 shares on April 6, 2026, a purchase totaling $34,972. The transaction was disclosed on a Form 4 filing with the SEC. The company has recently reorganized its multifamily assets into a new wholly owned entity and amended an equity distribution agreeme…
Mentor Capital CEO Chester Billingsley reported a purchase of 897 common shares at $0.063 per share on April 7, 2026, a transaction valued at approximately $56. The acquisition follows a sharp one-week decline in the stock and a recent conversion of Series Q preferred shares into common shares. Separately, Mentor Capital disclosed a change in its i…
Mark Casper, Executive Vice President and Chief Legal Officer at Marvell Technology, executed a sale of 6,900 shares of the company's common stock on April 6, 2026, generating proceeds of $755,205. The transaction leaves Casper with 4,023 shares held directly and an additional 10,263 shares held indirectly in trust. The disclosure arrives as Marvel…
